Adial Pharmaceuticals, Inc.
ADIL · NASDAQ
Bulios Fair Price
$2.73
38.0% downside
Current Price
$4.4
According to Bulios Fair Price, ADIL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Adial Pharmaceuticals (ADIL) is a pharmaceutical company focused on the development and commercialization of medications for the treatment of addictions and other disorders related to the central nervous system. The company specializes in researching innovative treatment methods aimed at helping patients overcome addictions and improve their quality of life. Adial Pharmaceuticals is known for its advanced clinical trials and commitment to providing effective therapeutic options. Adial Pharmaceuticals (ADIL) shares could be suitable for investors looking for opportunities in the biotechnology and pharmaceutical research sectors focused on addiction treatment.
Sector
Healthcare
Industry
Biotechnology
CEO
Cary John Claiborne
Employees
5
Headquarters
Glen Allen
Upcoming events
Earnings
Upcoming earnings report